Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma
Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of me...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 64; no. 2; pp. 473 - 487 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wolters Kluwer Health, Inc
01.08.2016
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473‐487) |
---|---|
AbstractList | Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α.
Conclusion:
TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (H
epatology
2016;64:473‐487) Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3 alpha . Conclusion: TIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1 alpha /miR-210/HIF-3 alpha . TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016; 64:473-487) Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down‐regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia‐like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC‐97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia‐inducible factor (HIF) 1 alpha, microRNA‐210 (miR‐210), and HIF‐3α. Conclusion: TIMP2 is frequently down‐regulated in human HCCs and its down‐regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF‐1α/miR‐210/HIF‐3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473‐487) UNLABELLEDCancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3α.CONCLUSIONTIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1α/miR-210/HIF-3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473-487). Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a concerted action of multiple proteolytic enzymes and their endogenous inhibitors. This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the context of hepatocellular carcinoma (HCC) metastasis. We found that TIMP2 was the most significantly down-regulated member among the TIMP family in human HCCs. Moreover, TIMP2 underexpression was frequent (41.8%; 23 of 55) in human HCCs and was significantly associated with liver invasion and poorer survival outcomes of HCC patients. Furthermore, stable silencing of TIMP2 in HCC cell lines enhanced cell invasive ability and ECM degradation associated with formation of invadopodia-like feature, suggesting that TIMP2 is a negative regulator of HCC metastasis. Using an orthotopic tumor xenograft model, we demonstrated that ectopic expression of TIMP2 open reading frame in the highly metastatic HCC cell line, MHCC-97L, significantly reduced HCC progression as well as pulmonary metastasis. Mechanistically, TIMP2 suppression, in a hypoxic environment, was induced through a regulatory feedback circuit consisting of hypoxia-inducible factor (HIF) 1 alpha, microRNA-210 (miR-210), and HIF-3α. TIMP2 is frequently down-regulated in human HCCs and its down-regulation is associated with aggressive tumor behavior and poorer patient outcome. Its suppression is under the regulation of a novel feedback circuit consisting of HIF-1α/miR-210/HIF-3α. TIMP2 is an important regulator of ECM degradation and HCC metastasis. (Hepatology 2016;64:473-487). |
Author | Lee, Joyce Man‐Fong Wong, Carmen Chak‐Lui Wong, Jack Chun‐Ming Kai, Alan Ka‐Lun Ng, Irene Oi‐Lin Chan, Lo Kong Lo, Regina Cheuk‐Lam |
AuthorAffiliation | 1 State Key Laboratory for Liver Research The University of Hong Kong Hong Kong 2 Department of Pathology The University of Hong Kong Hong Kong |
AuthorAffiliation_xml | – name: 2 Department of Pathology The University of Hong Kong Hong Kong – name: 1 State Key Laboratory for Liver Research The University of Hong Kong Hong Kong |
Author_xml | – sequence: 1 givenname: Alan Ka‐Lun surname: Kai fullname: Kai, Alan Ka‐Lun organization: The University of Hong Kong – sequence: 2 givenname: Lo Kong surname: Chan fullname: Chan, Lo Kong organization: The University of Hong Kong – sequence: 3 givenname: Regina Cheuk‐Lam surname: Lo fullname: Lo, Regina Cheuk‐Lam organization: The University of Hong Kong – sequence: 4 givenname: Joyce Man‐Fong surname: Lee fullname: Lee, Joyce Man‐Fong organization: The University of Hong Kong – sequence: 5 givenname: Carmen Chak‐Lui surname: Wong fullname: Wong, Carmen Chak‐Lui organization: The University of Hong Kong – sequence: 6 givenname: Jack Chun‐Ming surname: Wong fullname: Wong, Jack Chun‐Ming organization: The University of Hong Kong – sequence: 7 givenname: Irene Oi‐Lin surname: Ng fullname: Ng, Irene Oi‐Lin organization: The University of Hong Kong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27018975$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkt9qFDEUxoNU7LZ64QtIwBu92G7-TJKZG0Fq6y5ULFKvQ5I9002dSdbMjGXv-gTFV-mL9CF8ErPdtWhBEQIJ5_y-j3NOzh7aCTEAQs8pOaCEsMkClgesFEo9QiMqmBpzLsgOGhGmyLiivNpFe113QQipClY-Qbs5TstKiRG6fhcvw4-r7wnOh8b0PgYca3w2-3DKsF3h6ew4J-ntzaT1n_KLUTLZxPjtDd6KYlrhGmBujfuCnU9u8D2GsDDBQYfd-kq4hd50-fgO-4BzxVnnoGmyQcpMcj7E1jxFj2vTdPBse--jz8dHZ4fT8cnH97PDtydjJwqpxtTZohZg53xeWULmQlqhBHVGlmBtRRkDaYHWxhIJsna530Jap3jFlFMAfB-92fguB9vC3EHok2n0MvnWpJWOxus_M8Ev9Hn8pgVRBSc8G7zaGqT4dYCu163v1v2YAHHoNC0pLctKCPEfKJFFIWS5Rl8-QC_ikEKehGaSSsFpwdfUi9-Lv6_6169m4PUGcCl2XYL6HqFErzdG5_nru43J7OQB63x_twi5b9_8S3HpG1j93VpPj043ip9_H9gG |
CitedBy_id | crossref_primary_10_1007_s00018_018_2941_6 crossref_primary_10_1002_cam4_1618 crossref_primary_10_1007_s11033_023_08852_0 crossref_primary_10_1002_ijc_30730 crossref_primary_10_3390_cancers11121906 crossref_primary_10_1007_s10585_018_9930_x crossref_primary_10_1016_j_compbiomed_2024_108867 crossref_primary_10_1186_s12906_024_04569_0 crossref_primary_10_1016_j_nantod_2020_100934 crossref_primary_10_18632_aging_101587 crossref_primary_10_18632_oncotarget_15968 crossref_primary_10_1016_j_canlet_2024_217145 crossref_primary_10_2174_0929867329666220829095334 crossref_primary_10_1016_j_biopha_2018_01_162 crossref_primary_10_1371_journal_pone_0199827 crossref_primary_10_3390_ijms21134624 crossref_primary_10_3389_fphar_2022_991052 crossref_primary_10_1002_hep_31225 crossref_primary_10_1158_1541_7786_MCR_17_0256 crossref_primary_10_1002_hep_31221 crossref_primary_10_1002_jcp_29507 crossref_primary_10_1038_s41419_018_0616_8 crossref_primary_10_1155_2021_6699910 crossref_primary_10_1186_s13046_020_01733_5 crossref_primary_10_1002_1878_0261_13260 crossref_primary_10_1155_2022_3632764 crossref_primary_10_3724_abbs_2023231 crossref_primary_10_1002_mc_23585 crossref_primary_10_1002_jcp_29289 crossref_primary_10_3389_fcell_2022_1012254 crossref_primary_10_1016_j_cej_2022_138421 crossref_primary_10_1016_j_lfs_2021_119465 crossref_primary_10_1080_17474124_2017_1309281 crossref_primary_10_1016_j_omtn_2018_02_014 crossref_primary_10_1016_j_toxlet_2021_12_014 crossref_primary_10_1016_j_ejcb_2024_151386 crossref_primary_10_3390_cancers10120471 crossref_primary_10_1016_j_bbrc_2023_04_055 crossref_primary_10_1259_bjr_20190198 crossref_primary_10_1186_s12986_018_0323_6 crossref_primary_10_14814_phy2_15810 crossref_primary_10_3390_cancers15235553 crossref_primary_10_1038_s41388_023_02869_2 crossref_primary_10_1124_mol_116_107706 crossref_primary_10_3390_cells12242851 crossref_primary_10_1186_s12885_019_6429_z crossref_primary_10_1038_s41401_018_0014_x crossref_primary_10_1007_s10456_018_9600_2 crossref_primary_10_1631_jzus_B1900343 crossref_primary_10_2147_CMAR_S222878 crossref_primary_10_1016_j_cyto_2022_155917 crossref_primary_10_1016_j_yexcr_2021_112804 crossref_primary_10_1007_s10585_023_10224_8 crossref_primary_10_1186_s12943_021_01488_3 crossref_primary_10_3390_cells9010114 crossref_primary_10_3892_ol_2017_7349 crossref_primary_10_1007_s11523_018_0555_4 crossref_primary_10_1186_s12943_021_01440_5 crossref_primary_10_18632_oncotarget_16356 crossref_primary_10_1186_s12943_017_0688_6 crossref_primary_10_1515_hmbci_2023_0012 crossref_primary_10_1155_2024_5523283 crossref_primary_10_1002_1878_0261_12657 crossref_primary_10_3389_fmed_2021_686885 crossref_primary_10_1038_s41389_017_0011_9 crossref_primary_10_1021_acsomega_4c08947 crossref_primary_10_1016_j_critrevonc_2021_103236 crossref_primary_10_1111_jcmm_17808 crossref_primary_10_18632_oncotarget_20883 crossref_primary_10_1007_s12013_024_01624_y crossref_primary_10_14336_AD_2021_0315 crossref_primary_10_3390_cells10082161 crossref_primary_10_1016_j_drudis_2018_05_003 crossref_primary_10_1155_2020_1964219 crossref_primary_10_1007_s10565_022_09747_9 crossref_primary_10_1016_j_jpha_2024_101133 crossref_primary_10_3390_pharmaceutics15071887 crossref_primary_10_1158_1078_0432_CCR_17_2725 crossref_primary_10_1021_acs_biomac_8b00107 crossref_primary_10_3389_fgene_2020_580138 crossref_primary_10_1186_s12935_020_01719_5 crossref_primary_10_1186_s13046_020_01768_8 crossref_primary_10_1016_j_canlet_2021_11_006 crossref_primary_10_3389_fonc_2020_01620 crossref_primary_10_1155_2022_5262963 crossref_primary_10_3389_fonc_2021_605894 crossref_primary_10_1155_2020_2415324 crossref_primary_10_1016_j_clinre_2023_102077 crossref_primary_10_1007_s10930_017_9707_0 |
Cites_doi | 10.1016/j.molcel.2010.07.023 10.1038/nrm3141 10.1097/00006676-200410000-00008 10.1002/hep.24614 10.1016/S0140-6736(02)08649-X 10.1038/nature06174 10.1016/j.semcancer.2010.05.002 10.1038/nrg2101 10.1096/fj.05-3788com 10.1038/nrclinonc.2010.173 10.1002/hep.25512 10.1242/jcs.00063 10.1007/s10555-007-9105-8 10.1053/j.gastro.2010.10.006 10.1038/nature06487 10.1101/gad.1950610 10.1002/hep.25987 10.1016/S0092-8674(00)81235-0 10.4161/cc.6.22.4947 10.1002/ijc.1440 10.3322/canjclin.55.2.74 10.1002/path.3995 10.1002/hep.27320 10.1089/hum.2008.164 10.1002/hep.25979 10.1016/j.cell.2011.10.043 10.4161/auto.5656 10.1016/j.cell.2010.03.015 10.1053/jhep.2002.33156 10.1038/35107085 |
ContentType | Journal Article |
Copyright | 2016 The Authors. H published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. 2016. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2016 The Authors. H published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. – notice: 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. – notice: 2016. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 H94 K9. 7X8 5PM |
DOI | 10.1002/hep.28577 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Kai et al |
EISSN | 1527-3350 |
EndPage | 487 |
ExternalDocumentID | PMC5074303 27018975 10_1002_hep_28577 HEP28577 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: S.K. Yee Medical Research Fund 2011 – fundername: University Development Fund of The University of Hong Kong – fundername: Lee Shiu Family Foundation |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI ACZKN AFNMH AGQPQ AHQVU CITATION MEWTI WXSBR ACIJW CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 AAMMB ADSXY AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c5467-1cb4f5ebd3d9b00d56b5751ca68ebb9122e6be1fab06e6fc27046bc73927c7ee3 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 |
IngestDate | Thu Aug 21 13:56:50 EDT 2025 Fri Jul 11 00:20:19 EDT 2025 Fri Jul 11 08:51:24 EDT 2025 Wed Aug 13 09:02:30 EDT 2025 Thu Apr 03 07:02:56 EDT 2025 Tue Jul 01 03:33:45 EDT 2025 Thu Apr 24 22:52:01 EDT 2025 Wed Jan 22 16:53:39 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Attribution-NonCommercial 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5467-1cb4f5ebd3d9b00d56b5751ca68ebb9122e6be1fab06e6fc27046bc73927c7ee3 |
Notes | Potential conflict of interest: Nothing to report. The study was funded by the S.K. Yee Medical Research Fund 2011, University Development Fund of The University of Hong Kong, and Lee Shiu Family Foundation. I.O.L. Ng is Loke Yew Professor in Pathology. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28577 |
PMID | 27018975 |
PQID | 2616531435 |
PQPubID | 996352 |
PageCount | 15 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5074303 proquest_miscellaneous_1811889555 proquest_miscellaneous_1806445685 proquest_journals_2616531435 pubmed_primary_27018975 crossref_primary_10_1002_hep_28577 crossref_citationtrail_10_1002_hep_28577 wiley_primary_10_1002_hep_28577_HEP28577 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | August 2016 |
PublicationDateYYYYMMDD | 2016-08-01 |
PublicationDate_xml | – month: 08 year: 2016 text: August 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationTitleAlternate | Hepatology |
PublicationYear | 2016 |
Publisher | Wolters Kluwer Health, Inc John Wiley and Sons Inc |
Publisher_xml | – name: Wolters Kluwer Health, Inc – name: John Wiley and Sons Inc |
References | 2001; 94 2007; 449 2009; 20 2004; 29 2010; 39 2002; 35 2002; 359 2010; 141 2002; 115 2011; 54 2011; 12 2008; 4 2008; 1 2014; 60 2012; 55 2012; 227 2011; 8 2005; 2005 2011; 147 2010; 20 2005; 19 2010; 24 2013; 57 2008; 27 2007; 8 2007; 6 1996; 85 1998; 7 2011; 140 2008; 451 2005; 55 2001; 414 (hep28577-bib-0033-20241017) 2009; 20 (hep28577-bib-0032-20241017) 2002; 35 (hep28577-bib-0022-20241017) 2001; 414 (hep28577-bib-0025-20241017) 2011; 54 (hep28577-bib-0009-20241017) 2007; 449 (hep28577-bib-0010-20241017) 2008; 451 (hep28577-bib-0018-20241017) 2010; 24 (hep28577-bib-0024-20241017) 2007; 6 (hep28577-bib-0012-20241017) 2013; 57 (hep28577-bib-0030-20241017) 2012; 227 (hep28577-bib-0004-20241017) 2008; 1 (hep28577-bib-0017-20241017) 2011; 147 (hep28577-bib-0026-20241017) 2004; 29 (hep28577-bib-0020-20241017) 2012; 55 (hep28577-bib-0003-20241017) 2007; 8 (hep28577-bib-0015-20241017) 2013; 57 (hep28577-bib-0007-20241017) 2008; 27 (hep28577-bib-0002-20241017) 2005; 55 (hep28577-bib-0031-20241017) 2002; 359 (hep28577-bib-0029-20241017) 2010; 20 (hep28577-bib-0006-20241017) 2002; 115 (hep28577-bib-0019-20241017) 2010; 39 (hep28577-bib-0027-20241017) 2008; 4 (hep28577-bib-0005-20241017) 2010; 141 (hep28577-bib-0008-20241017) 2011; 8 (hep28577-bib-0011-20241017) 2011; 140 (hep28577-bib-0023-20241017) 2005; 19 (hep28577-bib-0001-20241017) 2001; 94 (hep28577-bib-0013-20241017) 2014; 60 (hep28577-bib-0014-20241017) 2005; 2005 (hep28577-bib-0016-20241017) 2011; 12 (hep28577-bib-0028-20241017) 1996; 85 (hep28577-bib-0021-20241017) 1998; 7 22262409 - J Pathol. 2012 Jul;227(3):275-85 20371345 - Cell. 2010 Apr 2;141(1):52-67 8646777 - Cell. 1996 May 31;85(5):683-93 17440531 - Nat Rev Genet. 2007 May;8(5):341-52 18612141 - Sci Signal. 2008 Jul 08;1(27):re6 25048396 - Hepatology. 2014 Nov;60(5):1645-58 16126907 - FASEB J. 2005 Sep;19(11):1396-406 22144109 - Hepatology. 2011 Dec;54(6):2064-75 22135159 - Hepatology. 2012 May;55(5):1453-61 17998805 - Cell Cycle. 2007 Nov 15;6(22):2810-6 22153071 - Cell. 2011 Dec 9;147(6):1233-47 16234508 - Sci STKE. 2005 Oct 18;2005(306):re12 12235282 - J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 15367889 - Pancreas. 2004 Oct;29(3):225-30 18185580 - Nature. 2008 Jan 10;451(7175):147-52 22829315 - Hepatology. 2013 Jan;57(1):152-61 11734856 - Nature. 2001 Nov 29;414(6863):550-4 21697900 - Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26 20797623 - Mol Cell. 2010 Aug 27;39(4):493-506 21045789 - Nat Rev Clin Oncol. 2011 Feb;8(2):75-84 21159816 - Genes Dev. 2010 Dec 15;24(24):2754-9 22821423 - Hepatology. 2013 Jan;57(1):131-9 11981766 - Hepatology. 2002 May;35(5):1164-71 15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 17898713 - Nature. 2007 Oct 11;449(7163):682-8 11668491 - Int J Cancer. 2001 Oct 15;94(2):153-6 12049862 - Lancet. 2002 May 18;359(9319):1734-9 18253086 - Autophagy. 2008 Apr;4(3):388-90 18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66 9840812 - Gene Expr. 1998;7(3):205-13 20951699 - Gastroenterology. 2011 Jan;140(1):322-31 20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8 19327024 - Hum Gene Ther. 2009 Apr;20(4):314-24 |
References_xml | – volume: 451 start-page: 147 year: 2008 end-page: 152 article-title: Endogenous human microRNAs that suppress breast cancer metastasis publication-title: Nature – volume: 20 start-page: 314 year: 2009 end-page: 324 article-title: Antisense hypoxia‐inducible factor‐1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats publication-title: Hum Gene Ther – volume: 57 start-page: 152 year: 2013 end-page: 161 article-title: RhoE is frequently down‐regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho‐kinase/myosin phosphatase target pathway publication-title: Hepatology – volume: 54 start-page: 2064 year: 2011 end-page: 2075 article-title: Hypoxia‐inducible microRNA‐210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma publication-title: Hepatology – volume: 1 start-page: re6 year: 2008 article-title: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase‐independent biological activities publication-title: Sci Signal – volume: 359 start-page: 1734 year: 2002 end-page: 1739 article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet – volume: 8 start-page: 75 year: 2011 end-page: 84 article-title: Metastamirs: a stepping stone towards improved cancer management publication-title: Nat Rev Clin Oncol – volume: 449 start-page: 682 year: 2007 end-page: 688 article-title: Tumour invasion and metastasis initiated by microRNA‐10b in breast cancer publication-title: Nature – volume: 115 start-page: 3719 year: 2002 end-page: 3727 article-title: Metalloproteinase inhibitors: biological actions and therapeutic opportunities publication-title: J Cell Sci – volume: 55 start-page: 74 year: 2005 end-page: 108 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin – volume: 140 start-page: 322 year: 2011 end-page: 331 article-title: The microRNA miR‐139 suppresses metastasis and progression of hepatocellular carcinoma by down‐regulating Rho‐kinase 2 publication-title: Gastroenterology – volume: 19 start-page: 1396 year: 2005 end-page: 1406 article-title: Human HIF‐3alpha4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma publication-title: FASEB J – volume: 4 start-page: 388 year: 2008 end-page: 390 article-title: A novel mammalian trans‐membrane protein reveals an alternative initiation pathway for autophagy publication-title: Autophagy – volume: 12 start-page: 413 year: 2011 end-page: 426 article-title: The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function publication-title: Nat Rev Mol Cell Biol – volume: 60 start-page: 1645 year: 2014 end-page: 1658 article-title: Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma publication-title: Hepatology – volume: 8 start-page: 341 year: 2007 end-page: 352 article-title: Genetic determinants of cancer metastasis publication-title: Nat Rev Genet – volume: 35 start-page: 1164 year: 2002 end-page: 1171 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology – volume: 414 start-page: 550 year: 2001 end-page: 554 article-title: Inhibitory PAS domain protein is a negative regulator of hypoxia‐inducible gene expression publication-title: Nature – volume: 94 start-page: 153 year: 2001 end-page: 156 article-title: Estimating the world cancer burden: Globocan 2000 publication-title: Int J Cancer – volume: 20 start-page: 161 year: 2010 end-page: 168 article-title: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion publication-title: Semin Cancer Biol – volume: 57 start-page: 131 year: 2013 end-page: 139 article-title: C‐terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C‐Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma publication-title: Hepatology – volume: 55 start-page: 1453 year: 2012 end-page: 1461 article-title: Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis publication-title: Hepatology – volume: 39 start-page: 493 year: 2010 end-page: 506 article-title: STAT3 activation of miR‐21 and miR‐181b‐1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer publication-title: Mol Cell – volume: 2005 start-page: re12 year: 2005 article-title: Integration of oxygen signaling at the consensus HRE publication-title: Sci STKE – volume: 27 start-page: 57 year: 2008 end-page: 66 article-title: The tumor microenvironment: regulation by MMP‐independent effects of tissue inhibitor of metalloproteinases‐2 publication-title: Cancer Metastasis Rev – volume: 24 start-page: 2754 year: 2010 end-page: 2759 article-title: Repression of the miR‐143/145 cluster by oncogenic Ras initiates a tumor‐promoting feed‐forward pathway publication-title: Genes Dev – volume: 141 start-page: 52 year: 2010 end-page: 67 article-title: Matrix metalloproteinases: regulators of the tumor microenvironment publication-title: Cell – volume: 147 start-page: 1233 year: 2011 end-page: 1247 article-title: An HNF4alpha‐miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis publication-title: Cell – volume: 29 start-page: 225 year: 2004 end-page: 230 article-title: Expression of vacuole membrane protein 1 (VMP1) in spontaneous chronic pancreatitis in the WBN/Kob rat publication-title: Pancreas – volume: 6 start-page: 2810 year: 2007 end-page: 2816 article-title: Dominant‐negative HIF‐3 alpha 4 suppresses VHL‐null renal cell carcinoma progression publication-title: Cell Cycle – volume: 227 start-page: 275 year: 2012 end-page: 285 article-title: In hepatocellular carcinoma miR‐519d is up‐regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2 publication-title: J Pathol – volume: 85 start-page: 683 year: 1996 end-page: 693 article-title: Localization of matrix metalloproteinase MMP‐2 to the surface of invasive cells by interaction with integrin alpha v beta 3 publication-title: Cell – volume: 7 start-page: 205 year: 1998 end-page: 213 article-title: Molecular characterization and chromosomal localization of a third alpha‐class hypoxia inducible factor subunit, HIF3alpha publication-title: Gene Expr – volume: 39 start-page: 493 year: 2010 ident: hep28577-bib-0019-20241017 article-title: STAT3 activation of miR‐21 and miR‐181b‐1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer publication-title: Mol Cell doi: 10.1016/j.molcel.2010.07.023 – volume: 7 start-page: 205 year: 1998 ident: hep28577-bib-0021-20241017 article-title: Molecular characterization and chromosomal localization of a third alpha‐class hypoxia inducible factor subunit, HIF3alpha publication-title: Gene Expr – volume: 12 start-page: 413 year: 2011 ident: hep28577-bib-0016-20241017 article-title: The ‘ins’ and ‘outs’ of podosomes and invadopodia: characteristics, formation and function publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm3141 – volume: 29 start-page: 225 year: 2004 ident: hep28577-bib-0026-20241017 article-title: Expression of vacuole membrane protein 1 (VMP1) in spontaneous chronic pancreatitis in the WBN/Kob rat publication-title: Pancreas doi: 10.1097/00006676-200410000-00008 – volume: 54 start-page: 2064 year: 2011 ident: hep28577-bib-0025-20241017 article-title: Hypoxia‐inducible microRNA‐210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.24614 – volume: 359 start-page: 1734 year: 2002 ident: hep28577-bib-0031-20241017 article-title: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08649-X – volume: 449 start-page: 682 year: 2007 ident: hep28577-bib-0009-20241017 article-title: Tumour invasion and metastasis initiated by microRNA‐10b in breast cancer publication-title: Nature doi: 10.1038/nature06174 – volume: 20 start-page: 161 year: 2010 ident: hep28577-bib-0029-20241017 article-title: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2010.05.002 – volume: 8 start-page: 341 year: 2007 ident: hep28577-bib-0003-20241017 article-title: Genetic determinants of cancer metastasis publication-title: Nat Rev Genet doi: 10.1038/nrg2101 – volume: 19 start-page: 1396 year: 2005 ident: hep28577-bib-0023-20241017 article-title: Human HIF‐3alpha4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma publication-title: FASEB J doi: 10.1096/fj.05-3788com – volume: 2005 start-page: re12 year: 2005 ident: hep28577-bib-0014-20241017 article-title: Integration of oxygen signaling at the consensus HRE publication-title: Sci STKE – volume: 8 start-page: 75 year: 2011 ident: hep28577-bib-0008-20241017 article-title: Metastamirs: a stepping stone towards improved cancer management publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2010.173 – volume: 55 start-page: 1453 year: 2012 ident: hep28577-bib-0020-20241017 article-title: Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis publication-title: Hepatology doi: 10.1002/hep.25512 – volume: 115 start-page: 3719 year: 2002 ident: hep28577-bib-0006-20241017 article-title: Metalloproteinase inhibitors: biological actions and therapeutic opportunities publication-title: J Cell Sci doi: 10.1242/jcs.00063 – volume: 27 start-page: 57 year: 2008 ident: hep28577-bib-0007-20241017 article-title: The tumor microenvironment: regulation by MMP‐independent effects of tissue inhibitor of metalloproteinases‐2 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-007-9105-8 – volume: 140 start-page: 322 year: 2011 ident: hep28577-bib-0011-20241017 article-title: The microRNA miR‐139 suppresses metastasis and progression of hepatocellular carcinoma by down‐regulating Rho‐kinase 2 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.10.006 – volume: 451 start-page: 147 year: 2008 ident: hep28577-bib-0010-20241017 article-title: Endogenous human microRNAs that suppress breast cancer metastasis publication-title: Nature doi: 10.1038/nature06487 – volume: 24 start-page: 2754 year: 2010 ident: hep28577-bib-0018-20241017 article-title: Repression of the miR‐143/145 cluster by oncogenic Ras initiates a tumor‐promoting feed‐forward pathway publication-title: Genes Dev doi: 10.1101/gad.1950610 – volume: 57 start-page: 152 year: 2013 ident: hep28577-bib-0012-20241017 article-title: RhoE is frequently down‐regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho‐kinase/myosin phosphatase target pathway publication-title: Hepatology doi: 10.1002/hep.25987 – volume: 85 start-page: 683 year: 1996 ident: hep28577-bib-0028-20241017 article-title: Localization of matrix metalloproteinase MMP‐2 to the surface of invasive cells by interaction with integrin alpha v beta 3 publication-title: Cell doi: 10.1016/S0092-8674(00)81235-0 – volume: 6 start-page: 2810 year: 2007 ident: hep28577-bib-0024-20241017 article-title: Dominant‐negative HIF‐3 alpha 4 suppresses VHL‐null renal cell carcinoma progression publication-title: Cell Cycle doi: 10.4161/cc.6.22.4947 – volume: 94 start-page: 153 year: 2001 ident: hep28577-bib-0001-20241017 article-title: Estimating the world cancer burden: Globocan 2000 publication-title: Int J Cancer doi: 10.1002/ijc.1440 – volume: 55 start-page: 74 year: 2005 ident: hep28577-bib-0002-20241017 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin doi: 10.3322/canjclin.55.2.74 – volume: 227 start-page: 275 year: 2012 ident: hep28577-bib-0030-20241017 article-title: In hepatocellular carcinoma miR‐519d is up‐regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2 publication-title: J Pathol doi: 10.1002/path.3995 – volume: 1 start-page: re6 year: 2008 ident: hep28577-bib-0004-20241017 article-title: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase‐independent biological activities publication-title: Sci Signal – volume: 60 start-page: 1645 year: 2014 ident: hep28577-bib-0013-20241017 article-title: Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.27320 – volume: 20 start-page: 314 year: 2009 ident: hep28577-bib-0033-20241017 article-title: Antisense hypoxia‐inducible factor‐1alpha augments transcatheter arterial embolization in the treatment of hepatocellular carcinomas in rats publication-title: Hum Gene Ther doi: 10.1089/hum.2008.164 – volume: 57 start-page: 131 year: 2013 ident: hep28577-bib-0015-20241017 article-title: C‐terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C‐Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.25979 – volume: 147 start-page: 1233 year: 2011 ident: hep28577-bib-0017-20241017 article-title: An HNF4alpha‐miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis publication-title: Cell doi: 10.1016/j.cell.2011.10.043 – volume: 4 start-page: 388 year: 2008 ident: hep28577-bib-0027-20241017 article-title: A novel mammalian trans‐membrane protein reveals an alternative initiation pathway for autophagy publication-title: Autophagy doi: 10.4161/auto.5656 – volume: 141 start-page: 52 year: 2010 ident: hep28577-bib-0005-20241017 article-title: Matrix metalloproteinases: regulators of the tumor microenvironment publication-title: Cell doi: 10.1016/j.cell.2010.03.015 – volume: 35 start-page: 1164 year: 2002 ident: hep28577-bib-0032-20241017 article-title: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma publication-title: Hepatology doi: 10.1053/jhep.2002.33156 – volume: 414 start-page: 550 year: 2001 ident: hep28577-bib-0022-20241017 article-title: Inhibitory PAS domain protein is a negative regulator of hypoxia‐inducible gene expression publication-title: Nature doi: 10.1038/35107085 – reference: 21159816 - Genes Dev. 2010 Dec 15;24(24):2754-9 – reference: 20371345 - Cell. 2010 Apr 2;141(1):52-67 – reference: 20951699 - Gastroenterology. 2011 Jan;140(1):322-31 – reference: 11981766 - Hepatology. 2002 May;35(5):1164-71 – reference: 22262409 - J Pathol. 2012 Jul;227(3):275-85 – reference: 16234508 - Sci STKE. 2005 Oct 18;2005(306):re12 – reference: 19327024 - Hum Gene Ther. 2009 Apr;20(4):314-24 – reference: 15761078 - CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 – reference: 20797623 - Mol Cell. 2010 Aug 27;39(4):493-506 – reference: 22829315 - Hepatology. 2013 Jan;57(1):152-61 – reference: 12049862 - Lancet. 2002 May 18;359(9319):1734-9 – reference: 11734856 - Nature. 2001 Nov 29;414(6863):550-4 – reference: 18185580 - Nature. 2008 Jan 10;451(7175):147-52 – reference: 9840812 - Gene Expr. 1998;7(3):205-13 – reference: 18253086 - Autophagy. 2008 Apr;4(3):388-90 – reference: 17440531 - Nat Rev Genet. 2007 May;8(5):341-52 – reference: 22135159 - Hepatology. 2012 May;55(5):1453-61 – reference: 15367889 - Pancreas. 2004 Oct;29(3):225-30 – reference: 25048396 - Hepatology. 2014 Nov;60(5):1645-58 – reference: 21045789 - Nat Rev Clin Oncol. 2011 Feb;8(2):75-84 – reference: 17998805 - Cell Cycle. 2007 Nov 15;6(22):2810-6 – reference: 21697900 - Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26 – reference: 22144109 - Hepatology. 2011 Dec;54(6):2064-75 – reference: 18058195 - Cancer Metastasis Rev. 2008 Mar;27(1):57-66 – reference: 17898713 - Nature. 2007 Oct 11;449(7163):682-8 – reference: 12235282 - J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 – reference: 16126907 - FASEB J. 2005 Sep;19(11):1396-406 – reference: 22821423 - Hepatology. 2013 Jan;57(1):131-9 – reference: 18612141 - Sci Signal. 2008 Jul 08;1(27):re6 – reference: 20470890 - Semin Cancer Biol. 2010 Jun;20(3):161-8 – reference: 22153071 - Cell. 2011 Dec 9;147(6):1233-47 – reference: 8646777 - Cell. 1996 May 31;85(5):683-93 – reference: 11668491 - Int J Cancer. 2001 Oct 15;94(2):153-6 |
SSID | ssj0009428 |
Score | 2.5233903 |
Snippet | Cancer metastasis is a multistep process that involves a series of tumor‐stromal interaction, including extracellular matrix (ECM) remodeling, which requires a... Cancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which requires a... UNLABELLEDCancer metastasis is a multistep process that involves a series of tumor-stromal interaction, including extracellular matrix (ECM) remodeling, which... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 473 |
SubjectTerms | Adult Aged Aged, 80 and over Animals Basic Helix-Loop-Helix Transcription Factors - metabolism Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - pathology Cell Line, Tumor Down-Regulation Ectopic expression Extracellular matrix Feedback Feedback, Physiological Female Gene Knockdown Techniques Hepatobiliary Malignancies Hepatocellular Carcinoma Hepatology Humans Hypoxia Hypoxia - metabolism Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Invasiveness Liver cancer Liver Neoplasms, Experimental - metabolism Liver Neoplasms, Experimental - pathology Lung Neoplasms - secondary Male Metastases Metastasis Mice, Inbred BALB C MicroRNAs - metabolism Middle Aged miRNA Neoplasm Metastasis Proteolysis Proteolytic enzymes Regulation Regulatory Pathways Tissue inhibitor of metalloproteinase 2 Tissue Inhibitor of Metalloproteinase-2 - metabolism Tumors Xenografts Young Adult |
Title | Down‐regulation of TIMP2 by HIF‐1α/miR‐210/HIF‐3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.28577 https://www.ncbi.nlm.nih.gov/pubmed/27018975 https://www.proquest.com/docview/2616531435 https://www.proquest.com/docview/1806445685 https://www.proquest.com/docview/1811889555 https://pubmed.ncbi.nlm.nih.gov/PMC5074303 |
Volume | 64 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZKD4gL_9AtpTKIA5fsJk7sJOKEoKstUtGqaqUekCLbcbRR2aRKsof2xBMgXqUv0ofgSZhxfspSQIhTongsje0Z-5t4_JmQV6n2Ax9WKkdyJh0kVHIUwHgnjLSX8dAwL7VZvh_F7Dj4cMJPNsib_ixMyw8x_HBDz7DzNTq4VPXkmjR0Yc7GLOIhniTHXC0ERIfX1FFxYO9VhajLxd3luGcVctlkqLm-Ft0AmDfzJH_Gr3YBmt4jn3rV27yT0_GqUWN98Qur43-27T652wFT-ra1pAdkwxQPye2Dbuv9Efn6HuL171--Ve3l9TCctMzo0f7BnFF1Tmf7Uyj0ri4ny_wQ3vDMTvvNv7qkXaWyOqcZLJdK6lOq80qv8oaaYoGWV1ONj4ouTSMBstZ5TfOCgo5QD7cXMF8WZCpQp1zKx-R4unf0buZ0lzk4muNk7GkVZNyo1E-RhjHlQuGWj5YiMkrFHmNGKONlUrnCiEzDuAVC6RDwW6hDY_wnZLMoC7NFqCtdljEV6zgKA4NBY-qmvkiN4RmSW43I635YE90xneOFG5-TlqOZJaB7Yvt3RF4OomctvcfvhHZ620g6D68TiDwFzF-ANkfkxVAMvok9IgtTrurEiwDwAUKN_ioDIV4Ucw4yT1tzGzSBPvCiOISScM0QBwHkBl8vKfKF5QjnCA1dH7rC2tmfG5fM9ub2ZfvfRZ-RO4AbRZsHuUM2m2plngM2a9QuucWC-a51xR-F1Dy_ |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEF6VIgEX_qGBAgsCiYsTe5312gcOiDRKaFNVVSr15nrXa2K1sSs7URVOPAHiQbj0QehD8CTM-K-EAuLSAydb3nG0Gc_MfuMdf0PIy1DZXRtWKiPgLDCQUMmQAOMN4Sor4kIzKyyqfLedwV73_T7fXyFf629hSn6I5oUbekYRr9HB8YV055w1dKKP28zlQlQllZt6cQIJW_5m2IOn-4qx_sb43cCoegoYimNMsJTsRlzL0A6RDTDkjsSdBxU4rpbSsxjTjtRWFEjT0U6kmIAEUioBMEIoobUNv3uFXMUO4sjU39s9J6vyukUnV8jzTNzP9moeI5N1mqkur34XIO3FysyfEXOx5PVvkW-1sspKl8P2fCbb6uMvPJL_izZvk5sV9qZvS2e5Q1Z0cpdcG1XVBffI5156knz_9CXTH6qmZjSN6Hg42mFULuhg2IdB6-y0M4134Qw_Syqv2WentLopzRY0AkQgA3VIVZypeTyjOpmgc-VU4SGjUz0LAJXncU7jhIJO4D7cQcGSYJDJYDrpNLhP9i5FGw_IapImeo1QMzBZxKSnPFd0NebFoRnaTqg1j5C_q0Ve13bkq4rMHXuKHPklDTXzYe5-8Txb5EUjelwymPxOaL02Rr8KYrkPybUDIRoAdYs8b4Yh_KBGgkSn89y3XMC0AMLdv8pAFut6nIPMw9K-m5mADizXEzAiliy_EUD68-WRJJ4UNOgc0a9pgyoKw_7zn_MHGzvFyaN_F31Grg_Goy1_a7i9-ZjcAJjslGWf62R1ls31E4CiM_m0iACUHFy2k_wAPNCb7A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VIlVcEP8ECiwIJC4m9trrtQ8cEGmUUFpFqJV6M971WLEgdmQnQrnxBIj34NQX6UPwJMzYjktUQFx6suUdW-udmd1vPONvGXueGNdzcaWyYiliiwiVLI0w3lKBcVKpQDhJXeV76I-OvXcn8mSL_Vj_C9PwQ3Qf3Mgz6vmaHHyepP1z0tApzF-JQCrVVlTuw-oLxmvV6_EAlftCiOHe0duR1W4pYBlJU4JjtJdK0ImbEBlgIn1NiQcT-wFoHTpCgK_BSWNt--CnRiiMH7VRiCKUUQAuPvcKu0rJRaofE97knOHXqzdyxTDPpnR2uKYxskW_6-rm4ncB0V4szPwdMNcr3vAGu95CVf6msa2bbAvyW2znoE3G32bfBhjB__z6vWy2s0cF8yLlR-ODieB6xUfjITY6Z6f9WfYBz-gvnuaae3bK25uKcsVTXEB1bD5xk5VmmS045FOyxYobOpR8BosYQWyVVTzLOb4m3kcJB6qgRZkSu1PM4jvs-FJ0cZdt50UO9xm3Y1ukQocmDJQHFEYmduL6CYBMie6qx16uxz0yLfc5bcHxOWpYm0WEfY9qFfXYs0503hB-_Elod628qPX5KsJY1McZDfFnjz3tmtFbaUTiHIplFTkBQkDErME_ZTDoC0IpUeZeYw9dT3AMnCBU2KI2LKUTILbwzZY8m9as4ZLAou3iUNQ29feXi0Z7k_rkwf-LPmE7k8Ewej8-3H_IriGo9JsiyV22vSiX8AiB20I_rh2Gs4-X7aG_ALNYWao |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Down%E2%80%90regulation+of+TIMP2+by+HIF%E2%80%901%CE%B1%2FmiR%E2%80%90210%2FHIF%E2%80%903%CE%B1+regulatory+feedback+circuit+enhances+cancer+metastasis+in+hepatocellular+carcinoma&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Kai%2C+Alan+Ka%E2%80%90Lun&rft.au=Chan%2C+Lo+Kong&rft.au=Lo%2C+Regina+Cheuk%E2%80%90Lam&rft.au=Lee%2C+Joyce+Man%E2%80%90Fong&rft.date=2016-08-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=64&rft.issue=2&rft.spage=473&rft.epage=487&rft_id=info:doi/10.1002%2Fhep.28577&rft_id=info%3Apmid%2F27018975&rft.externalDocID=PMC5074303 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |